---
layout: default
title: Betaxolol Hcl
parent: 僅模型預測 (L5)
nav_order: 139
evidence_level: L5
indication_count: 0
---

# Betaxolol Hcl
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# BETAXOLOL HCL: Drug Repurposing Evaluation — Awaiting Prediction Data

## One-Sentence Summary

Betaxolol HCl is a selective beta-1 adrenergic receptor blocker, available in Malaysia with 2 registered products.
The TxGNN model has **not yet generated predicted indications** for this drug,
and critical data gaps (MOA, safety profile, license details) remain to be addressed before evaluation can proceed.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | *(License details pending — registration data fields are empty)* |
| Predicted New Indication | **None** — no TxGNN prediction available |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (No prediction or supporting evidence) |
| Malaysia Market Status | ✓ Marketed (已上市) |
| Number of Registrations | 2 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

There is currently **no TxGNN prediction** to evaluate for Betaxolol HCl. The `predicted_indications` array is empty, meaning the model has not yet identified candidate new indications for this drug.

Currently, detailed mechanism of action data is not available in this evidence pack. Based on known pharmacological classification, Betaxolol HCl is a selective beta-1 adrenergic receptor antagonist (beta-blocker). It is typically used in oral form for the management of hypertension, and in ophthalmic form for the reduction of intraocular pressure in open-angle glaucoma or ocular hypertension. Its selectivity for beta-1 receptors over beta-2 receptors is a distinguishing characteristic compared to non-selective beta-blockers.

Before a repurposing evaluation can be conducted, the TxGNN prediction pipeline must be run for this compound, and the resulting candidate indications must be populated into the evidence pack. Additionally, the DrugBank ID mapping (currently null) needs to be resolved to enable automated evidence collection.

---

## Clinical Trial Evidence

Currently no related clinical trials registered — no predicted indication available to search against.

---

## Literature Evidence

Currently no related literature available — no predicted indication available to search against.

---

## Malaysia Market Information

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|------|------|------|------|
| *(empty)* | *(empty)* | *(empty)* | *(empty)* |
| *(empty)* | *(empty)* | *(empty)* | *(empty)* |

> **Note:** 2 registrations are recorded in the regulatory database, but all license detail fields (authorization number, product name, dosage form, approved indication) are empty. These need to be retrieved from the NPRA database.

---

## Safety Considerations

> Please refer to the package insert for safety information.
>
> All safety data fields (key warnings, contraindications, drug interactions) are currently unavailable. These must be retrieved before any repurposing evaluation can proceed — this is flagged as a **Blocking** data gap (DG001).

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This evidence pack is missing critical data at every level: no TxGNN predicted indications, no DrugBank ID mapping, no MOA data, empty license details, and no safety information. A meaningful repurposing evaluation cannot be performed until these gaps are resolved.

**To proceed, the following is needed:**

1. **DrugBank ID mapping** — Resolve the DrugBank ID for Betaxolol HCl (query returned 1 result per the log, but the ID was not populated; likely `DB00195`)
2. **TxGNN prediction** — Run the KG and/or DL prediction pipeline to generate candidate new indications
3. **NPRA license details** — Populate authorization numbers, product names, dosage forms, and approved indication text for the 2 registered products
4. **Safety data (Blocking)** — Download and parse the package insert PDF from the NPRA website to extract warnings, contraindications, and drug interactions
5. **MOA data** — Query DrugBank API to retrieve mechanism of action details
6. **Evidence collection** — Once a predicted indication is available, run ClinicalTrials.gov, PubMed, and ICTRP collectors
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

